These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
465 related articles for article (PubMed ID: 28560619)
21. Cariprazine: First Global Approval. McCormack PL Drugs; 2015 Nov; 75(17):2035-43. PubMed ID: 26510944 [TBL] [Abstract][Full Text] [Related]
22. Cariprazine, an orally active D2/D3 receptor antagonist, for the potential treatment of schizophrenia, bipolar mania and depression. Gründer G Curr Opin Investig Drugs; 2010 Jul; 11(7):823-32. PubMed ID: 20571978 [TBL] [Abstract][Full Text] [Related]
23. The role of dopamine D Calabrese F; Tarazi FI; Racagni G; Riva MA CNS Spectr; 2020 Jun; 25(3):343-351. PubMed ID: 31010452 [TBL] [Abstract][Full Text] [Related]
24. The dopamine D₃-preferring D₂/D₃ dopamine receptor partial agonist, cariprazine, reverses behavioural changes in a rat neurodevelopmental model for schizophrenia. Watson DJG; King MV; Gyertyán I; Kiss B; Adham N; Fone KCF Eur Neuropsychopharmacol; 2016 Feb; 26(2):208-224. PubMed ID: 26723167 [TBL] [Abstract][Full Text] [Related]
25. The effect of cariprazine on hostility associated with schizophrenia: post hoc analyses from 3 randomized controlled trials. Citrome L; Durgam S; Lu K; Ferguson P; Laszlovszky I J Clin Psychiatry; 2016 Jan; 77(1):109-15. PubMed ID: 26845266 [TBL] [Abstract][Full Text] [Related]
26. Cariprazine:New dopamine biased agonist for neuropsychiatric disorders. De Deurwaerdère P Drugs Today (Barc); 2016 Feb; 52(2):97-110. PubMed ID: 27092339 [TBL] [Abstract][Full Text] [Related]
27. Cariprazine, a new, orally active dopamine D2/3 receptor partial agonist for the treatment of schizophrenia, bipolar mania and depression. Veselinović T; Paulzen M; Gründer G Expert Rev Neurother; 2013 Nov; 13(11):1141-59. PubMed ID: 24175719 [TBL] [Abstract][Full Text] [Related]
28. Cariprazine in bipolar disorder: clinical efficacy, tolerability, and place in therapy. Citrome L Adv Ther; 2013 Feb; 30(2):102-13. PubMed ID: 23361832 [TBL] [Abstract][Full Text] [Related]
29. Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial. Durgam S; Cutler AJ; Lu K; Migliore R; Ruth A; Laszlovszky I; Németh G; Meltzer HY J Clin Psychiatry; 2015 Dec; 76(12):e1574-82. PubMed ID: 26717533 [TBL] [Abstract][Full Text] [Related]
30. Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [(11)C]-(+)-PHNO. Girgis RR; Slifstein M; D'Souza D; Lee Y; Periclou A; Ghahramani P; Laszlovszky I; Durgam S; Adham N; Nabulsi N; Huang Y; Carson RE; Kiss B; Kapás M; Abi-Dargham A; Rakhit A Psychopharmacology (Berl); 2016 Oct; 233(19-20):3503-12. PubMed ID: 27525990 [TBL] [Abstract][Full Text] [Related]
32. [Cariprazine in schizophrenia with predominantly negative symptoms: early effects of therapy (observational study)]. Smulevich AB; Ivanov SV; Yakhin KK; Voronova EI; Kharkova GS; Skurygina EI; Konohova MV; Beybalaeva TZ; Katok AA Zh Nevrol Psikhiatr Im S S Korsakova; 2020; 120(12):67-72. PubMed ID: 33459543 [TBL] [Abstract][Full Text] [Related]
33. [The newer antipsychotic cariprazine (reagila): perspectives for use in different stages of schizophrenia therapy]. Ivanov SV; Voronova EI Zh Nevrol Psikhiatr Im S S Korsakova; 2021; 121(9):139-144. PubMed ID: 34693702 [TBL] [Abstract][Full Text] [Related]
34. Mechanism of action of cariprazine. Stahl SM CNS Spectr; 2016 Apr; 21(2):123-7. PubMed ID: 26956157 [TBL] [Abstract][Full Text] [Related]
35. Effects of cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology. Neill JC; Grayson B; Kiss B; Gyertyán I; Ferguson P; Adham N Eur Neuropsychopharmacol; 2016 Jan; 26(1):3-14. PubMed ID: 26655189 [TBL] [Abstract][Full Text] [Related]
36. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials. Citrome L; Meng X; Hochfeld M; Stahl SM Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738 [TBL] [Abstract][Full Text] [Related]
37. Cariprazine in the treatment of schizophrenia: a proof-of-concept trial. Durgam S; Litman RE; Papadakis K; Li D; Németh G; Laszlovszky I Int Clin Psychopharmacol; 2016 Mar; 31(2):61-8. PubMed ID: 26655732 [TBL] [Abstract][Full Text] [Related]
38. Long-Term Remission With Cariprazine Treatment in Patients With Schizophrenia: A Post Hoc Analysis of a Randomized, Double-Blind, Placebo-Controlled, Relapse Prevention Trial. Correll CU; Potkin SG; Zhong Y; Harsányi J; Szatmári B; Earley W J Clin Psychiatry; 2019 Jan; 80(2):. PubMed ID: 30695290 [TBL] [Abstract][Full Text] [Related]
39. Preclinical pharmacodynamic and pharmacokinetic characterization of the major metabolites of cariprazine. Kiss B; Némethy Z; Fazekas K; Kurkó D; Gyertyán I; Sághy K; Laszlovszky I; Farkas B; Kirschner N; Bolf-Terjéki E; Balázs O; Lendvai B Drug Des Devel Ther; 2019; 13():3229-3248. PubMed ID: 31571826 [TBL] [Abstract][Full Text] [Related]
40. Global improvement with cariprazine in the treatment of bipolar I disorder and schizophrenia: A pooled post hoc analysis. Durgam S; Earley W; Lu K; Németh G; Laszlovszky I; Volk S; Litman RE Int J Clin Pract; 2017 Dec; 71(12):. PubMed ID: 29119668 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]